ArticleOsteoarthritis and cartilage2025
Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study.
Article in Osteoarthritis and cartilage, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivePeople with osteoarthritis (OA) commonly experience flares. Whether COVID-19 vaccination triggers OA flares is unknown.
designAdults with OA enrolled in a COVID-19 Rheumatology Registry were invited to participate in a case-crossover study. Vaccine data were ascertained from self-report and electronic health records (EHR). OA was identified using coding algorithms and validated via EHR. Participants reported flare and non-flare periods. Vaccine exposures in the 2-, 7-, and 14-day "lookback windows" prior to OA flares were compared to vaccine exposures during similar non-flare ("control") periods.
results279 participants had validated OA, and 136 (49%) contributed at least one flare and one control period. Mean age was 68 years [SD ±8], 82% female, 87% White, 62% knee OA, 56% hip OA, 37% hand/wrist OA and 60% had >= one anatomic location of OA. 525 COVID-19 vaccine doses were recorded, and participants reported 374 OA flares: 30% were mild, 55% were moderate, and 14% were severe. OA flares were not associated with COVID-19 vaccination 2 or 7 days prior (odds ratios [OR] 0.69 [95% confidence interval (CI): 0.28, 1.66], OR 0.54 [95% CI: 0.27, 1.07], respectively). In the 14-day lookback window, fewer flares occurred after vaccination (OR 0.57 [95% CI: 0.34, 0.97], p=0.039). Analyses stratified on sex, age, knee or hand OA, vaccine brand, and dose showed no increased association between COVID-19 vaccination and OA flares.
conclusionThe lack of positive association between COVID-19 vaccination and OA flare in any primary or secondary analysis provides reassurance regarding the use of COVID-19 vaccines in people with OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.